Improving Management of High-Risk Cardiovascular Patients
Release Date: July 17, 2006 Expiration Date: July 17, 2007
Upon completion of one or more activities within this program, participants will be able to:
Understand the importance of hypertension, dyslipidemia, diabetes, and atherosclerosis as risk factors for cardiovascular morbidity and mortality.
Review the recent studies comparing selective and nonselective beta-blockers, angiotensin receptor blockers, and ACE (angiotensin-converting enzyme) inhibitors in the treatment of hypertension and heart failure.
Identify appropriate evidence-based risk reduction strategies for high-risk patient groups, including African American, elderly, post-MI (myocardial infarction), and diabetic patients, and particularly for patients with multiple risk factors.
Identify clinical features associated with heart failure in the setting of preserved systolic dysfunction.
Faculty and Disclosures
Content collaborators at INNOVIA Education Institute have disclosed no
relevant financial relationships.
The peer reviewer for this activity, Eileen Hsich, MD, has disclosed no
relevant financial relationships.
New Guideline Goals: The Assessment of ARB Use in the Treatment of Heart Failure
Meet the Experts: A One-hour CME-certified Interactive Audioconference
Release date: February 2006 Expiration date: February 2007
After completing this activity, participants will be able to:
Explain how chronic activation of the renin-angiotensin-aldosterone system (RAAS can influence the progression of heart failure (HF)
Discuss the implications of recent clinical trials showing that some angiotensin receptor blockers (ARBs) can improve outcomes in patients with low or normal left ventricular ejection fraction (LVEF) HF
Discuss applications of the new American College of Cardiology (ACC)/American Heart Association (AHA) guidelines
Detail how patients should be monitored to prevent complications related to complex pharmacotherapy regimens (e.g., hyperkalemia)
New Perspectives and Controversies in Cardiology: A CME-certified Webinar from the 2005 American Heart Association Satellite Symposium
Release Date: January 2006 Expiration Date: January 2007
Upon completion of this educational activity, the participant should be able to:
Discuss the use of beta blockers and angiotensin receptor blockers (ARBs) in patients with diabetes and the metabolic syndrome who are at high risk for the development of Stage A HF
Review the contribution of the metabolic syndrome to the occurrence of HF
Provide perspective on the role of beta blockers in an era of implantable cardioverter-defibrillator (ICD) implantation in patients with HF
Contrast the process of remodeling in men vs women with HF
Compare and contrast the American College of Cardiology (ACC)/American Heart Association (AHA) and European Society of Cardiology (ESC) guidelines for HF
New Guideline Goals: The Assessment of ARB Use in the Treatment of Heart Failure
Implications of New Data on the Updated ACC/AHA Guidelines
Release date: December 2005 Expiration date: December 2006
Upon completion of this activity, participants will be able to:
Discuss applications of the new American College of Cardiology (ACC)/American Heart Association (AHA) guidelines
Examine a stepwise approach to managing the HF patient
Detail how patients should be monitored to prevent complications related to complex pharmacotherapy regimens (eg, hyperkalemia)
Flash Player is required to view the webinar and is available as a free download by clicking here.
New Guideline Goals: The Assessment of ARB Use in the Treatment of Heart Failure
Chronic Heart Failure: The Scope of the Problem
Release date: December 2005 Expiration date: December 2006
Upon completion of this activity, participants will be able to:
Explain how chronic activation of the renin-angiotensin-aldosterone system (RAAS) can influence the progression of heart failure (HF)
Discuss the implications of recent clinical trials showing that some angiotensin receptor blockers (ARBs) can improve outcomes in patients with low or normal left ventricular ejection fraction (LVEF) HF
Discuss applications of the new American College of Cardiology (ACC)/American Heart Association (AHA) guidelines
Detail how patients should be monitored to prevent complications related to complex pharmacotherapy regimens (eg, hyperkalemia)
Flash Player is required to view the webinar and is available as a free download by clicking here.
New Guideline Goals: The Assessment of ARB Use in the Treatment of Heart Failure
Review of the Evidence from Recent Trials: Management of Chronic Heart Failure
Release date: December 2005 Expiration date: December 2006
Upon completion of this activity, participants will be able to:
Explain how chronic activation of the renin-angiotensin-aldosterone system (RAAS) can influence the progression of heart failure (HF)
Discuss the implications of recent clinical trials showing that some angiotensin receptor blockers (ARBs) can improve outcomes in patients with low or normal left ventricular ejection fraction (LVEF) HF
Examine a stepwise approach to managing the HF patient, including why and when to use ARBs
Flash Player is required to view the webinar and is available as a free download by clicking here.
Putting Evidence into Practice: A Practical Guide to Managing Heart Failure
Upon completion of this educational activity, the participant should be able to:
Discuss the rising incidence of heart failure (HF) and the increasing burden it places on the health-care system
Recognize the pathophysiology of HF by stage
Assess signs and symptoms of HF
Define the role of renin-angiotensin-aldosterone system activation in the cardiovascular disease continuum
Recognize the importance of neurohormonal blockade in the prevention and treatment of HF
Prioritize the use of angiotensin-converting enzyme inhibitors, beta blockers, and angiotensin receptor blockers in the management of the HF continuum
Recognize when to consider adding aldosterone antagonists, vasodilators, or
digoxin
Apply evidence-based treatment recommendations in HF management
Implement an algorithm to treat HF
Recognize the advent of payment for quality: "Good therapy is cost effective."
Neurohormonal Blockade Across the Spectrum of Cardiovascular Disease
Upon completion of this educational activity, the participant should be able to:
Describe the pathophysiology of hypertension, its clinical implications in diabetes, coronary artery disease, and heart failure, and resultant target organ damage
Discuss the role of insulin resistance in the development of atherosclerosis and other cardiovascular endpoints
Understand the role of sympathetic nervous system (SNS) and renin-angiotensin-aldosterone system (RAAS) activation in cardiovascular disease progression
Determine the role of SNS and RAAS blockade in the management of hypertension, left ventricular hypertrophy, and heart failure
Hypertension to Heart Failure in Diabetes
Upon completion of this educational activity, the participant should be able to:
Describe the pathophysiology of hypertension, its clinical implications in diabetes, coronary artery disease, and heart failure, and resultant target organ damage
Discuss the role of insulin resistance in the development of atherosclerosis and other cardiovascular endpoints
Understand the role of sympathetic nervous system (SNS) and renin-angiotensin-aldosterone system (RAAS) activation in cardiovascular disease progression
Determine the role of SNS and RAAS blockade in the management of hypertension, left ventricular hypertrophy, and heart failure
Please note that this PowerPoint file has been zipped to compress its size. Windows users can use WinZip® to decompress this archive, and Mac OS users can use StuffIt®.
Management Of Target-organ Damage In Cardiovascular Disease: A Case-based Approach
Upon completion of this educational activity, the participant should be able to:
Discuss the rising prevalence of hypertension and its public health implications
Describe the pathophysiology of hypertension and resultant target-organ damage, including diabetes, renal insufficiency, left ventricular hypertrophy, and heart failure
Understand the role of sympathetic nervous system and renin-angiotensin-aldosterone system activation in cardiovascular disease progression
Determine the role of renin-angiotensin-aldosterone system blockade in the management of hypertension, renal insufficiency, left ventricular hypertrophy, and heart failure
Advanced Perspectives on Beta Blockers in Heart Failure and CVD
Upon completion of this educational activity, the participant should be able to:
Understand
the role of beta blockers across the spectrum of cardiovascular
disease, with particular focus on their role in the treatment of heart
failure.
Discuss the misconceptions surrounding and barriers to the use of beta blockers in cardiovascular disease.
Evolving Concepts
In Heart Failure Treatment
Upon completion of this educational activity, the participant should be able to:
Discuss the rising prevalence of heart failure and its public health implications
Describe the pathophysiology, stages, and diagnosis of heart failure
Understand the role of sympathetic nervous system and renin-angiotensin-aldosterone system activation in cardiovascular disease progression
Understand the importance of neurohormonal blockade in the treatment of heart failure
Determine the role of angiotensin-converting enzyme inhibitors, beta blockers, and angiotensin receptor blockers in management of the heart failure continuum
The Stroke of Time: Controlling High Blood Pressure
This CME monograph was developed with the support of an educational grant from AstraZeneca as a scientific and clinical resource on the management of patients with hypertension and stroke. This activity was designed to educate physicians who have an interest in the association between hypertension and stroke and how hypertension management can decrease risk of stroke.
Upon completion of this activity, participants should be able to:
Describe the rationale for aggressive treatment of hypertension, even for patients with hypertension.
Describe the importance of the target-organ protective effects of reninangiotensin-aldosterone system (RAAS) blockade, particularly as it relates
to stroke prevention.
Discuss the vascular protective benefits of effectively lowering blood pressure and the significance of RAAS blockade in treating elderly patients with
hypertension.
Describe the emerging role of angiotensin receptor blockers alone and in
combination with other hypertensive agents.
